E. Beaudouin, M. Morisset, G. Kanny, and D. Moneret-vautrin, Angio-oedèmes iatrogènes : particularités cliniques. La Revue de Médecine Interne, Juin, vol.27, issue.2, pp.73-75, 2006.
DOI : 10.1016/j.revmed.2006.03.011

E. Frigas and U. Nzeako, Angioedema, Clinical Reviews in Allergy & Immunology, vol.23, issue.2, pp.217-232, 2002.
DOI : 10.1385/CRIAI:23:2:217

L. Bouillet, I. Boccon-gibod, and C. Massot, Les angioedèmes bradykiniques héréditaires ou acquis. La Revue de Médecine Interne, 2010.
DOI : 10.1016/j.revmed.2009.11.021

M. Bas, V. Adams, T. Suvorava, T. Niehues, T. Hoffmann et al., Nonallergic angioedema: role of bradykinin, Allergy, vol.77, issue.6, pp.842-856, 2007.
DOI : 10.1111/j.1398-9995.2006.01197.x

J. Chevrant-breton, D. Mazéas, M. Bagot, M. Henry, J. Goasguen et al., Acquired angioneurotic edema caused by acquired deficiency of C1 esterase inhibitor disclosing lymphoproliferative syndrome. Apropos of a case, review of the literature], Ann Dermatol Venereol, vol.109, issue.12, pp.1049-1056, 1982.

J. Jackson, R. Sim, A. Whelan, and C. Feighery, An IgG autoantibody which inactivates C1??-inhibitor, Nature, vol.84, issue.6090, pp.722-724, 1986.
DOI : 10.7326/0003-4819-84-5-580

J. Nussberger, M. Cugno, C. Amstutz, M. Cicardi, A. Pellacani et al., Plasma bradykinin in angio-oedema. The Lancet, Juin, vol.6351, issue.9117, pp.1693-1697, 1998.

I. Wagenaar-bos, C. Drouet, E. Aygören-pursun, K. Bork, C. Bucher et al., Functional C1-Inhibitor diagnostics in hereditary angioedema: Assay evaluation and recommendations, Journal of Immunological Methods, vol.338, issue.1-2, pp.14-20, 2008.
DOI : 10.1016/j.jim.2008.06.004

URL : https://hal.archives-ouvertes.fr/hal-00400706

E. Pappalardo, M. Cicardi, C. Duponchel, A. Carugati, S. Choquet et al., Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema, Journal of Allergy and Clinical Immunology, vol.106, issue.6, pp.1147-1154, 2000.
DOI : 10.1067/mai.2000.110471

A. Agostoni, E. Aygören-pürsün, K. Binkley, A. Blanch, K. Bork et al., Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond, Journal of Allergy and Clinical Immunology, vol.114, issue.3, pp.51-131, 2004.
DOI : 10.1016/j.jaci.2004.06.047

O. Fain, Les angioedèmes bradykiniques acquis. La Revue de Médecine Interne 31, pp.32-34, 2010.
DOI : 10.1016/j.revmed.2010.03.005

K. Bork, B. Fischer, and G. Dewald, Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy, The American Journal of Medicine, vol.114, issue.4, pp.294-298, 2003.
DOI : 10.1016/S0002-9343(02)01526-7

G. Kanny, W. Pichler, M. Morisset, P. Franck, M. B. Kohler et al., T cell???mediated reactions to iodinated contrast media: Evaluation by skin and lymphocyte activation tests, Journal of Allergy and Clinical Immunology, vol.115, issue.1, pp.179-185, 2005.
DOI : 10.1016/j.jaci.2004.09.012

A. Agostoni, M. Cicardi, M. Cugno, L. Zingale, D. Gioffré et al., Angioedema due to angiotensin-converting enzyme inhibitors, Immunopharmacology, vol.44, issue.1-2, pp.21-25, 1999.
DOI : 10.1016/S0162-3109(99)00107-1

A. Leimgruber, Widal triad (Asthma-Nasal polyposis-aspirin intolerance): an inflammatory metabolism abnormality], Rev Med Suisse, vol.1, issue.1, pp.15-23, 2005.

H. Nygren and G. Dahlén, Complement-dependent histamine release from rat peritoneal mast cells, induced by lipopolysaccharides from Bacteroides oralis, Fusobacterium nucleatum and Veillonella parvula, Journal of Oral Pathology and Medicine, vol.2, issue.2, pp.87-94, 1981.
DOI : 10.1902/jop.1977.48.9.497

J. Wan and A. Bezjak, Superior Vena Cava Syndrome, Emergency Medicine Clinics of North America, vol.27, issue.2, pp.243-255, 2009.
DOI : 10.1016/j.emc.2009.01.003

A. Abouzahir, P. Chaurin, G. Coutant, and J. Garcin, Le syndrome de Gleich. Un cas et revue de la littérature. La Revue de Médecine Interne, Fév, vol.26, issue.2, pp.137-140, 2005.

R. Rogers, MELKERSSON-ROSENTHAL SYNDROME AND OROFACIAL GRANULOMATOSIS, Dermatologic Clinics, vol.14, issue.2, pp.371-380, 1996.
DOI : 10.1016/S0733-8635(05)70363-6

G. Wang, C. Li, and T. Gao, Blepharochalasis: A Rare Condition Misdiagnosed as Recurrent Angioedema, Archives of Dermatology, vol.145, issue.4, pp.498-499, 2009.
DOI : 10.1001/archdermatol.2009.19

M. Lahiri and A. Y. Lim, Angioedema and systemic lupus erythematosus--a complementary association? Ann Acad Med Singapore, Fév, vol.36, issue.2, pp.142-147, 2007.

R. Trabado, A. , R. Miranda, J. Carreño, S. et al., Angioedema as a single manifestation of carcinoid syndrome in a bronchial carcinoid tumor, Allergologia et Immunopathologia, vol.32, issue.4, pp.235-237, 2004.
DOI : 10.1016/S0301-0546(04)79246-0

Y. Tay and B. Ong, Cutaneous angiosarcoma presenting as recurrent angio-oedema of the face, British Journal of Dermatology, vol.16, issue.6, pp.1346-1348, 2000.
DOI : 10.1001/archderm.135.9.1035

T. Sollecito, S. Derossi, J. Stewart, D. Ettlin, and C. Mowad, Elephantiasis nostras of the lips, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, vol.84, issue.3, pp.297-300, 1997.
DOI : 10.1016/S1079-2104(97)90347-4

F. Mcduffie, W. Sams, J. Maldonado, P. Andreini, D. Conn et al., Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome, Mayo Clin. Proc. Mai, vol.48, issue.5, pp.340-348, 1973.

H. Guyton, Le systeme rénine-angiotensine : son rôle dans le controle de la pression et dans l'hypertension. Précis de physiologie médicale, deuxiéme édition, IVchapitre, vol.19, pp.221-228, 2000.

T. Unger, The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. The American Journal of Cardiology, Mai, vol.2291, issue.10, pp.28-34, 2003.

M. Böhm, Angiotensin Receptor Blockers versus Angiotensin-Converting Enzyme Inhibitors: Where Do We Stand Now? The American Journal of Cardiology, Aoû, vol.6100, issue.3, pp.38-44, 2007.

S. Wassmann and G. Nickenig, Pathophysiological regulation of the AT1-receptor and implications for vascular disease, Journal of Hypertension, vol.24, issue.Suppl 1, pp.15-21
DOI : 10.1097/01.hjh.0000220402.53869.72

P. Gohlke, W. Linz, B. Scholkens, I. Kuwer, S. Bartenbach et al., Angiotensinconverting enzyme inhibition improves cardiac function. Role of bradykinin, Hypertension, 1994.
DOI : 10.1161/01.hyp.23.4.411

URL : http://hyper.ahajournals.org/content/hypertensionaha/23/4/411.full.pdf

R. Skrbic and R. Igic, Seven decades of angiotensin Peptides, imshealth.com 2007 top therapeutic Classes by RX. Consulté le, pp.1945-1950, 1939.

S. Solomon, M. Rice, A. Jablonski, K. Jose, P. Domanski et al., Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial, Circulation, vol.114, issue.1, pp.26-31, 2006.
DOI : 10.1161/CIRCULATIONAHA.105.592733

H. Peng, O. Carretero, N. Vuljaj, T. Liao, A. Motivala et al., Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action, Circulation, vol.112, issue.16, pp.2436-2445, 2005.
DOI : 10.1161/CIRCULATIONAHA.104.528695

R. Wexler, D. Carini, J. Duncia, A. Johnson, G. Wells et al., Rationale for the Chemical Development of Angiotensin II Receptor Antagonists, American Journal of Hypertension, vol.5, issue.12_Pt_2, 1992.
DOI : 10.1093/ajh/5.12.209S

M. Weber, Telmisartan in High-Risk Cardiovascular Patients. The American Journal of Cardiology, Jan, vol.4105, issue.1, pp.36-43, 2010.

F. Xu, C. Mao, Y. Liu, L. Wu, Z. Xu et al., Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney, Current Medicinal Chemistry, vol.16, issue.28, p.3701, 2009.
DOI : 10.2174/092986709789105000

K. Chaudhary, R. Nistala, and A. Whaley-connell, Is there a future for direct renin inhibitors?, Expert Opinion on Investigational Drugs, vol.118, issue.1, pp.653-661
DOI : 10.1185/03007990802336541

D. Sica, Direct Renin Inhibition-Commonly Asked Questions. The Journal of Clinical Hypertension, pp.871-875, 2008.
DOI : 10.1111/j.1751-7176.2008.00039.x

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2008.00039.x/pdf

J. Basile, Lessons learned from the ONTARGET and TRANSCEND trials, Current Atherosclerosis Reports, vol.372, issue.5, pp.371-376
DOI : 10.7326/0003-4819-117-3-234

A. Kaplan, K. Joseph, and M. Silverberg, Pathways for bradykinin formation and inflammatory disease, Journal of Allergy and Clinical Immunology, vol.109, issue.2, pp.195-209, 2002.
DOI : 10.1067/mai.2002.121316

J. Sharma, Hypertension and the bradykinin system, Current Hypertension Reports, vol.26, issue.3, pp.178-181
DOI : 10.1007/s11906-009-0032-7

R. Sabroe and A. Black, Angiotensin???converting enzyme (ACE) inhibitors and angio???oedema, British Journal of Dermatology, vol.119, issue.2, pp.153-158, 1997.
DOI : 10.1016/S0140-6736(94)91774-4

D. Regoli, N. Allogho, S. Rizzi, A. Gobeil, and F. , Bradykinin receptors and their antagonists, European Journal of Pharmacology, vol.348, issue.1, pp.1-10, 1998.
DOI : 10.1016/S0014-2999(98)00165-4

J. Hall, Bradykinin receptors General Pharmacology: The Vascular System, pp.1-6, 1997.

D. Regoli, . Calo-'g, A. Rizzi, G. Bogoni, F. Gobeil et al., Bradykinin receptors and receptor ligands (with special emphasis on vascular receptors) Regulatory Peptides, 1996.

B. Liu, J. Linley, X. Du, X. Zhang, L. Ooi et al., The acute nociceptive signals induced by bradykinin in rat sensory neurons are mediated by inhibition of M-type K+ channels and activation of Ca2+-activated Cl??? channels, Journal of Clinical Investigation, vol.120, issue.4, pp.1240-1252
DOI : 10.1172/JCI41084DS1

J. Su, R. Houel, F. Heloire, F. Barbe, F. Beverelli et al., Stimulation of Bradykinin B1 Receptors Induces Vasodilation in Conductance and Resistance Coronary Vessels in Conscious Dogs : Comparison With B2 Receptor Stimulation, Circulation, vol.101, issue.15, pp.1848-1853, 2000.
DOI : 10.1161/01.CIR.101.15.1848

J. Xu, O. Carretero, Y. Sun, E. Shesely, N. Rhaleb et al., Role of the B1 Kinin Receptor in the Regulation of Cardiac Function and Remodeling After Myocardial Infarction, Hypertension, vol.45, issue.4, pp.747-753, 2005.
DOI : 10.1161/01.HYP.0000153322.04859.81

C. Shima, M. Majima, M. A. Katori, and . Stable-metabolite, A Stable Metabolite, Arg-Pro-Pro-Gly-Phe, of Bradykinin in the Degradation Pathway in Human Plasma., The Japanese Journal of Pharmacology, vol.60, issue.2, pp.111-119, 1992.
DOI : 10.1254/jjp.60.111

G. Molinaro, M. Cugno, M. Perez, Y. Lepage, N. Gervais et al., Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a Slower Degradation of des-Arginine9-Bradykinin, Journal of Pharmacology and Experimental Therapeutics, vol.303, issue.1, 2002.
DOI : 10.1124/jpet.102.038067

K. Kim, S. Kumar, W. Simmons, and N. Brown, Inhibition of Aminopeptidase P Potentiates Wheal Response to Bradykinin in Angiotensin-Converting Enzyme Inhibitor-Treated Humans, Journal of Pharmacology and Experimental Therapeutics, vol.292, issue.1, pp.295-298, 2000.

J. Lefebvre, L. Murphey, T. Hartert, J. Shan, R. Simmons et al., Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema. Hypertension, Fév, vol.139, issue.2, pp.460-464, 2002.

M. Prechel, L. Orawski, W. Maggiora, and . Simmons, Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung, J Pharmacol Exp Ther. Déc, vol.275, issue.3, pp.1136-1178, 1995.

A. Adam, M. Cugno, G. Molinaro, M. Perez, Y. Lepage et al., Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. The Lancet, Juin, vol.15359, issue.9323, pp.2088-2089, 2002.

T. Hoover, M. Lippmann, E. Grouzmann, F. Marceau, and P. Herscu, Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors, Clinical & Experimental Allergy, 20097.
DOI : 10.1111/j.1365-2222.2009.03323.x

J. Willemse, D. Chen, and D. Hendriks, Major carboxypeptidase N deficiency, Clinica Chimica Acta, vol.389, issue.1-2, pp.181-182, 2008.
DOI : 10.1016/j.cca.2007.11.008

A. Coats, Omapatrilat- the story of Overture and Octave, International Journal of Cardiology, vol.86, issue.1, pp.1-4, 2002.
DOI : 10.1016/S0167-5273(02)00389-3

A. Zanchi, M. Maillard, and M. Burnier, Recent clinical trials with omapatrilat: New developments, Current Hypertension Reports, vol.12, issue.3, pp.346-352
DOI : 10.1161/01.CIR.103.6.904

D. Campbell, H. Krum, and M. Esler, Losartan Increases Bradykinin Levels in Hypertensive Humans. Circulation, pp.315-320, 2005.

A. Scheen, Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes, Obesity and Metabolism, pp.648-658, 2010.

J. Byrd, K. Touzin, S. Sile, J. Gainer, C. Yu et al., Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor Associated Angioedema, Hypertension, vol.51, issue.1, pp.141-147, 2008.
DOI : 10.1161/HYPERTENSIONAHA.107.096552

N. Brown, S. Byiers, D. Carr, M. Maldonado, and B. Warner, Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema, Hypertension, vol.54, issue.3, pp.516-523, 2009.
DOI : 10.1161/HYPERTENSIONAHA.109.134197

C. Grattan, S. Powell, and F. Humphreys, Management and diagnostic guidelines for urticaria and angio-oedema, British Journal of Dermatology, vol.81, issue.4, pp.708-714, 2001.
DOI : 10.1046/j.1365-2133.1998.02175.x

M. Bas, N. Kirchhartz, J. Hochfeld, C. Tüllmann, S. Kumpf et al., Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema, Journal of Allergy and Clinical Immunology, vol.121, issue.4, pp.969-975, 2008.
DOI : 10.1016/j.jaci.2008.01.071

M. Bas, T. Hoffmann, H. Bier, and G. Kojda, Increased C-reactive protein in ACE-inhibitor-induced angioedema, British Journal of Clinical Pharmacology, vol.268, issue.2, pp.233-238, 2005.
DOI : 10.1016/S0024-3205(01)01129-8

J. Roberts and R. Wuerz, Clinical characteristics of angiotensinconverting enzyme inhibitorinduced angioedema. Annals of Emergency Medicine, Mai, vol.20, issue.5, pp.555-558, 1991.

E. Elinav, Y. Rabinowitz, M. Lorberbaum, and V. Nisanewitz, Episodic Macroglossia as the Sole Manifestation of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema, Annals of Otology, Rhinology & Laryngology, vol.113, issue.3
DOI : 10.1177/000348940311200714

J. Mccabe, C. Stork, D. Mailloux, and M. Su, Penile angioedema associated with the use of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers, American Journal of Health-System Pharmacy, vol.65, issue.5, pp.420-421, 2008.
DOI : 10.2146/ajhp070299

T. Byrne, D. Douglas, and M. Landis, Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors? Mayo Clin Proc, pp.1201-1205, 2000.

T. Schmidt and K. Mcgrath, Angiotensin-Converting Enzyme Inhibitor Angioedema of the Intestine: A Case Report and Review of the Literature, The American Journal of the Medical Sciences, vol.324, issue.2, pp.106-108, 2002.
DOI : 10.1097/00000441-200208000-00011

Y. Oike, Y. Ogata, D. Higashi, T. Matsumura, and Y. Numata, Fatal Angioedema Associated with Enalapril., Internal Medicine, vol.32, issue.4, pp.308-310, 1993.
DOI : 10.2169/internalmedicine.32.308

P. Sarkar, G. Nicholson, and G. Hall, Revue sommaire sur les implications anesth??siques de l?????d??me de Quincke et des inhibiteurs de l???enzyme de conversion de l???ngiotensine, Canadian Journal of Anesthesia/Journal canadien d'anesth??sie, vol.25, issue.Suppl2, pp.994-1003, 2006.
DOI : 10.1177/000348940111000906

A. Chiu, K. Newkirk, B. Davidson, A. Burningham, E. Krowiak et al., Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Multicenter Review and an Algorithm for Airway Management, Annals of Otology, Rhinology & Laryngology, vol.32, issue.9, pp.834-840, 2001.
DOI : 10.1016/S0091-6749(96)70151-3

J. Starr, W. George, A. Brasher, D. Rao, and . Posey, Erythema Marginatum and Hereditary Angioedema, Southern Medical Journal, vol.97, issue.10, pp.948-50, 2004.
DOI : 10.1097/01.SMJ.0000140850.22535.FA

P. Schmidt, M. Hirschl, and F. Trautinger, Treatment of angiotensin-converting enzyme inhibitor???related angioedema with the bradykinin B2 receptor antagonist icatibant, Journal of the American Academy of Dermatology, vol.63, issue.5, 2010.
DOI : 10.1016/j.jaad.2010.03.023

M. Bas, J. Greve, K. Stelter, H. Bier, T. Stark et al., Therapeutic Efficacy of Icatibant in Angioedema Induced by Angiotensin-Converting Enzyme Inhibitors: A Case Series, Annals of Emergency Medicine, vol.56, issue.3, 2010.
DOI : 10.1016/j.annemergmed.2010.03.032

E. Nielsen and S. Gramstad, Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate, Acta Anaesthesiologica Scandinavica, vol.5, issue.Suppl. 1, pp.120-122, 20061.
DOI : 10.2165/00126839-200405060-00006

N. Brown, W. Ray, M. Snowden, and M. Griffin, Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema*, Clinical Pharmacology & Therapeutics, vol.8, issue.1, 1996.
DOI : 10.1097/00004872-199112006-00164

J. Gainer, J. Nadeau, D. Ryder, and N. Brown, Increased sensitivity to bradykinin among African Americans, Journal of Allergy and Clinical Immunology, vol.98, issue.2, pp.283-287, 1996.
DOI : 10.1016/S0091-6749(96)70151-3

J. Ducroix, S. Outurquin, B. Benabes-jezraoui, V. Gras, G. Chaby et al., Angiooedèmes et inhibiteurs de l'enzyme de conversion de l'angiotensine : à propos de 19 cas. La Revue de Médecine Interne, Juillet, vol.25, issue.7, pp.501-506, 2004.

J. Kostis, H. Kim, J. Rusnak, T. Casale, A. Kaplan et al., Incidence and Characteristics of Angioedema Associated With Enalapril, Archives of Internal Medicine, vol.165, issue.14, pp.1637-1642, 2005.
DOI : 10.1001/archinte.165.14.1637

M. Bas, T. Hoffmann, B. Tiemann, V. Dao, C. Bantis et al., Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema, British Journal of Clinical Pharmacology, vol.16, issue.2, pp.179-186, 2010.
DOI : 10.1161/01.CIR.97.14.1411

Q. Duan, B. Nikpoor, M. Dubé, G. Molinaro, I. Meijer et al., A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I???Converting Enzyme Inhibitors, The American Journal of Human Genetics, vol.77, issue.4, pp.617-626, 2005.
DOI : 10.1086/496899

A. Woodard-grice, A. Lucisano, J. Byrd, E. Stone, W. Simmons et al., Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema, Pharmacogenetics and Genomics, vol.20, issue.9, pp.532-536, 2010.
DOI : 10.1097/FPC.0b013e32833d3acb

W. Vleeming, J. G. Van-amsterdam, D. J. Stricker, and . Wildt, ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf, pp.171-88, 1998.

L. Bouillet, Les angioedèmes bradykiniques (AO) : définition clinique. Fiche de travail CHU Grenoble, 2001.

M. Cicardi, L. Zingale, L. Bergamaschini, and A. Agostoni, Angioedema Associated With Angiotensin-Converting Enzyme Inhibitor Use, Archives of Internal Medicine, vol.164, issue.8, pp.910-913, 2004.
DOI : 10.1001/archinte.164.8.910

N. Brown, M. Snowden, and . Griffin, Recurrent angiotensin-converting enzyme inhibitor-associated angioedema, JAMA. Juillet, vol.16278, issue.3, pp.232-235, 1997.

B. Dahlöf, R. Devereux, S. Kjeldsen, J. S. Beevers, G. De-faire et al., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, The Lancet, vol.359, issue.9311, pp.995-1003, 2002.
DOI : 10.1016/S0140-6736(02)08089-3

A. Borazan, H. Ustun, and A. Yilmaz, Angioedema induced by angiotensin II blocker telmisartan, Allergy, vol.90, issue.5, pp.454-454, 2003.
DOI : 10.1056/NEJM199512073332316

L. Howes and D. Tran, Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf, pp.73-79, 2002.

R. Abdi, M. Victor, C. J. Dong, and . Lee, Angiotensin II Receptor Blocker???Associated Angioedema: On the Heels of ACE Inhibitor Angioedema, Pharmacotherapy, vol.90, issue.6, pp.1173-1178, 2002.
DOI : 10.1001/archderm.133.8.972

E. Slater, H. Merrill, P. J. Guess, W. Roylance, W. Cooper et al., Clinical Profile of Angioedema Associated With Angiotensin Converting-Enzyme Inhibition, JAMA: The Journal of the American Medical Association, vol.260, issue.7, pp.967-70, 1988.
DOI : 10.1001/jama.1988.03410070095035

R. Ferner, J. Simpson, and M. Rawlins, Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme., BMJ, vol.294, issue.6580, pp.1119-1120, 1987.
DOI : 10.1136/bmj.294.6580.1119

Z. Israili and W. Hall, Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy, Annals of Internal Medicine, vol.117, issue.3, pp.234-276, 1992.
DOI : 10.7326/0003-4819-117-3-234

C. Blais, J. Rouleau, N. Brown, Y. Lepage, D. Spence et al., Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitorassociated angioedema, Immunopharmacology, vol.43, pp.2-3293, 1999.

J. Byrd, A. Shreevatsa, P. Putlur, D. Foretia, L. Mcalexander et al., Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor???induced peritracheal edema, Journal of Allergy and Clinical Immunology, vol.120, issue.2, pp.403-408, 2007.
DOI : 10.1016/j.jaci.2007.04.012

Y. Tan, F. Hutchison, and A. Jaffa, kinin receptors, American Journal of Physiology-Heart and Circulatory Physiology, vol.286, issue.3, pp.926-932, 2004.
DOI : 10.1097/00004872-199816121-00026

F. Roskiewicz, I. Andriamanana, V. Gras-champel, M. Andrejak, and Z. Massy, Angio-??d??mes iatrog??nes: r??le des??inhibiteurs de??l'enzyme de??conversion et??des??antagonistes des??r??cepteurs ????l'angiotensine II (sartans), N??phrologie & Th??rapeutique, vol.3, issue.3, pp.89-95, 2007.
DOI : 10.1016/j.nephro.2007.03.003

H. Bluestein, A. Todd, A. Hoover, . Suryadevara-banerji, A. Carlos et al., Angiotensin-converting enzyme inhibitor???induced angioedema in a community hospital emergency department, Annals of Allergy, Asthma & Immunology, vol.103, issue.6, pp.502-509, 2009.
DOI : 10.1016/S1081-1206(10)60267-0

B. Malde, J. Regalado, A. Paul, and . Greenberger, Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, Annals of Allergy, Asthma & Immunology, vol.98, issue.1, pp.57-63, 2007.
DOI : 10.1016/S1081-1206(10)60860-5

O. The and . Investigators, Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events, New England Journal of Medicine, vol.3358, issue.15, pp.1547-1559, 2008.